Results: 4

    Policy brief on improving access to artemisinin-based combination therapies for malaria in the East African community

    The World Health Organization (WHO) since June 1998 has advocated for the use of artemisinin-based combination therapies (ACTs) in countries where Plasmodium falciparum malaria is resistant to traditional antimalarial therapies such as chloroquine, sulfadoxine-pyrimethamine, and amodiaquine (19;22). In 2...

    Policy brief on improving access to artemisinin-based combination therapies for malaria in Cameroon

    Malaria is the major cause of illness in Cameroon, responsible for 40 percent of medical consultations. For this reason, the Head of State along with his African Union peers in April 2000 and 2006 undertook to achieve universal access to malaria control interventions, including effective treatment (10;12...

    Policy brief on improving access to artemisinin-based combination therapies for malaria control in Ethiopia

    Malaria in Ethiopia is one of the leading causes of death (21.8 percent), consultation in outpatient departments (17.8 percent) and hospital admissions (14.1 percent) (2;14). To overcome this problem, the Malaria Control Program (Federal Ministry of Health) has designed a communitybased malaria treatment...

    Policy brief on improving access to artemisinin-based combination therapies for malaria in Mozambique

    Malaria is a major cause of morbidity and mortality in Mozambique. Approximately 6 million cases are reported each year. Malaria accounts for approximately 40 percent of all outpatient visits and 60 percent of pediatric hospital admissions. It is the leading cause of death among children admitted to pedi...